Andra AP fonden Purchases New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Andra AP fonden acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 3,100 shares of the biopharmaceutical company’s stock, valued at approximately $753,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the last quarter. Quattro Financial Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 4,809 shares during the period. Westpac Banking Corp grew its stake in shares of Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 566 shares during the last quarter. Finally, Plato Investment Management Ltd raised its holdings in shares of Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 4,346 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares in the company, valued at approximately $3,275,669.19. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the sale, the executive vice president now directly owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,148 shares of company stock worth $25,658,824. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $261.73 on Friday. The company has a market capitalization of $33.11 billion, a PE ratio of -97.66 and a beta of 0.38. The company has a 50-day simple moving average of $258.25 and a two-hundred day simple moving average of $193.82. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue was up 107.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.21) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Leerink Partners boosted their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. JPMorgan Chase & Co. lifted their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Finally, The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. Seven research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.